Table 4.
Therapeutic theory of MSCs-derived exosomes in the experimental UC
Source of exosome | Therapeutic theory | Molecular target | References |
---|---|---|---|
UC-MSCs |
↓ Macrophage infiltration ↓ IL-1β, IL-6, IL-7, TNF-α, iNOS ↑ IL-10, IP-10 |
Ubiquitin components Ubiquitin-associated molecules |
[49, 50] |
↓ Macrophage pyroptosis | NLRP3 | [51] | |
↓ Th17 cells | TSG-6 | [52] | |
↑ Th2 cells | TSG-6 | [52] | |
AD-MSCs |
↑ Treg cells ↑ IL‐4, IL‐10, IL-13, TGF‐β ↓ IL-1β, IL-6, IL-12, IL-17, TNF-α, IFN‐γ |
Not defined | [68, 69] |
BM-MSCs |
↑Treg cells ↓Th17 cells |
Stat3 inhibition mediated by exosomal miR-125a and miR-125b | [70] |
OE-MSCs |
↑ Treg cells ↑ TGF-β, IL-10 ↓ Th1/Th17 cells ↓ IL-17, IFN-γ |
Not defined | [71] |
↓ and ↑ show the decrease and the increase, respectively
MSCs mesenchymal stem cells, UC-MSCs umbilical cord-derived MSCs, AD-MSCs adipose-derived MSCs, BM-MSCs bone marrow-derived MSCs, OE-MSCs olfactory ecto-MSCs, TNF-α tumor necrosis factor-α, TSG-6 TNF-α stimulated gene 6, NLRP3 NOD-like receptor family, pyrin domain-containing 3